Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
77 hedge funds and large institutions have $156M invested in Generation Bio in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 9 closing their positions.
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
25% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 24
4% more funds holding
Funds holding: 74 → 77 (+3)
0.07% more ownership
Funds ownership: 8.27% → 8.34% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
30% less capital invested
Capital invested by funds: $224M → $156M (-$67.2M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$2.72M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.06M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$873K |
| 4 |
BlackRock
New York
|
+$797K |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$489K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.71M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.25M |
| 3 |
Millennium Management
New York
|
-$406K |
| 4 |
JP Morgan Chase
New York
|
-$307K |
| 5 |
Two Sigma Investments
New York
|
-$275K |
GBIO Hedge Fund Activity: Q2 2024 in Review
77 of the 6,928 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q2 2024, worth a combined $156M — down 30% from $224M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new GBIO positions and 9 closed out — a net gain of 3 holders — while 30 added to existing stakes and 24 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $2.72M. The largest seller was PFM Health Sciences, cutting an estimated $2.71M.
- 77 institutional investors held Generation Bio (GBIO) as of Q2 2024, up from 74 in Q1 2024.
- Funds reported $156M of Generation Bio stock for Q2 2024, down 30% quarter-over-quarter.
- 12 funds opened new Generation Bio positions in Q2 2024 and 9 closed out, a net change of +3 holders.
- The largest Generation Bio buyer in Q2 2024 was Baker Bros. Advisors, an estimated $2.72M added.
- The largest Generation Bio seller in Q2 2024 was PFM Health Sciences, an estimated $2.71M sold.
Based on aggregated 13F filings for Q2 2024.